FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220783039> ?p ?o ?g. }

• W4220783039 endingPage "752" @default.
• W4220783039 startingPage "741" @default.
• W4220783039 abstract "The main IgG4 antibody-mediated neurological disorders (IgG4-ND) include MuSK myasthenia; CIDP with nodal/paranodal antibodies to Neurofascin-155, contactin-1/caspr-1, or pan-neurofascins; anti-LGI1 and CASPR2-associated limbic encephalitis, Morvan syndrome, or neuromyotonia; and several cases of the anti-IgLON5 and anti-DPPX-spectrum CNS diseases. The paper is centered on the clinical spectrum of IgG4-ND and their immunopathogenesis highlighting the unique functional effects of the IgG4 subclass compared to IgG1-3 antibody subclasses. The IgG4 antibodies exert pathogenic effects on their targeted antigens by blocking enzymatic activity or disrupting protein-protein interactions affecting signal transduction pathways, but not by activating complement, binding to inhibitory FcγRIIb receptor or engaging in cross-linking of the targeted antigen with immune complex formation as the IgG1-IgG3 antibody subclasses do. IgG4 can even inhibit the classical complement pathway by affecting the affinity of IgG1-2 subclasses to C1q binding. Because the IgG4 antibodies do not trigger inflammatory processes or complement-mediated immune responses, the conventional anti-inflammatory therapies, especially with IVIg, immunosuppressants, and plasmapheresis, are ineffective or not sufficiently effective in inducing long-term remissions. In contrast, aiming at the activated plasmablasts connected with IgG4 antibody production is a meaningful therapeutic target in IgG4-ND. Indeed, data from large series of patients with MuSK myasthenia, CIDP with nodal/paranodal antibodies, and anti-LGI1 and CASPR2-associated syndromes indicate that B cell depletion therapy with rituximab exerts long-lasting clinical remissions by targeting memory B cells and IgG4-producing CD20-positive short-lived plasma cells. Because IgG4 antibody titers seem reduced in remissions and increased in exacerbation, they may serve as potential biomarkers of treatment response supporting further the pathogenic role of self-reacting B cells. Controlled trials are needed in IgG4-ND not only with rituximab but also with the other anti-B cell agents that target CD19/20, especially those like obexelimab and obinutuzumab, that concurrently activate the inhibitory FcγRIIb receptors which have low binding affinity to IgG4, exerting a more prolonged anti-B cell action affecting also antigen presentation and cytotoxic T cells. Antibody therapies targeting FcRn, testing those anti-FcRn inhibitors that effectively catabolize the IgG4 antibody subclass, may be especially promising." @default.
• W4220783039 created "2022-04-03" @default.
• W4220783039 creator A5090062651 @default.
• W4220783039 date "2022-03-15" @default.
• W4220783039 modified "2023-09-26" @default.
• W4220783039 title "Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies" @default.
• W4220783039 cites W1497904783 @default.
• W4220783039 cites W1566573763 @default.
• W4220783039 cites W1862461292 @default.
• W4220783039 cites W1874142858 @default.
• W4220783039 cites W1967064220 @default.
• W4220783039 cites W1975756380 @default.
• W4220783039 cites W1984730781 @default.
• W4220783039 cites W1986864699 @default.
• W4220783039 cites W1991027093 @default.
• W4220783039 cites W2002434755 @default.
• W4220783039 cites W2008134500 @default.
• W4220783039 cites W2010334618 @default.
• W4220783039 cites W2010335787 @default.
• W4220783039 cites W2013362643 @default.
• W4220783039 cites W2018803381 @default.
• W4220783039 cites W2043698418 @default.
• W4220783039 cites W2045746485 @default.
• W4220783039 cites W2051666192 @default.
• W4220783039 cites W2068641392 @default.
• W4220783039 cites W2072765129 @default.
• W4220783039 cites W2073714591 @default.
• W4220783039 cites W2085431115 @default.
• W4220783039 cites W2093149203 @default.
• W4220783039 cites W2101252880 @default.
• W4220783039 cites W2109238964 @default.
• W4220783039 cites W2144759405 @default.
• W4220783039 cites W2146002808 @default.
• W4220783039 cites W2157199750 @default.
• W4220783039 cites W2160988692 @default.
• W4220783039 cites W2162856159 @default.
• W4220783039 cites W2169656611 @default.
• W4220783039 cites W2181258698 @default.
• W4220783039 cites W2254260605 @default.
• W4220783039 cites W2274046219 @default.
• W4220783039 cites W2303467806 @default.
• W4220783039 cites W2315610003 @default.
• W4220783039 cites W2460848699 @default.
• W4220783039 cites W2465872742 @default.
• W4220783039 cites W2593303678 @default.
• W4220783039 cites W2593828537 @default.
• W4220783039 cites W2595114075 @default.
• W4220783039 cites W2605154961 @default.
• W4220783039 cites W2742758273 @default.
• W4220783039 cites W2772705597 @default.
• W4220783039 cites W2789766907 @default.
• W4220783039 cites W2792613800 @default.
• W4220783039 cites W2795881860 @default.
• W4220783039 cites W2796377352 @default.
• W4220783039 cites W2904124424 @default.
• W4220783039 cites W2922433707 @default.
• W4220783039 cites W2971536190 @default.
• W4220783039 cites W2972221943 @default.
• W4220783039 cites W2989586610 @default.
• W4220783039 cites W3006118591 @default.
• W4220783039 cites W3016201069 @default.
• W4220783039 cites W3022437762 @default.
• W4220783039 cites W3026110171 @default.
• W4220783039 cites W3045262132 @default.
• W4220783039 cites W3046678058 @default.
• W4220783039 cites W3081066467 @default.
• W4220783039 cites W3087106109 @default.
• W4220783039 cites W3090586214 @default.
• W4220783039 cites W3095467523 @default.
• W4220783039 cites W3115713292 @default.
• W4220783039 cites W3129235818 @default.
• W4220783039 cites W3170470841 @default.
• W4220783039 cites W3180930680 @default.
• W4220783039 cites W3187581748 @default.
• W4220783039 cites W3190148184 @default.
• W4220783039 cites W3194931521 @default.
• W4220783039 cites W3195491897 @default.
• W4220783039 cites W3208942552 @default.
• W4220783039 cites W3213865552 @default.
• W4220783039 cites W4210246676 @default.
• W4220783039 cites W4226156572 @default.
• W4220783039 cites W4226325697 @default.
• W4220783039 doi "https://doi.org/10.1007/s13311-022-01210-1" @default.
• W4220783039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35290608" @default.
• W4220783039 hasPublicationYear "2022" @default.
• W4220783039 type Work @default.
• W4220783039 citedByCount "12" @default.
• W4220783039 countsByYear W42207830392022 @default.
• W4220783039 countsByYear W42207830392023 @default.
• W4220783039 crossrefType "journal-article" @default.
• W4220783039 hasAuthorship W4220783039A5090062651 @default.
• W4220783039 hasBestOaLocation W42207830391 @default.
• W4220783039 hasConcept C147483822 @default.
• W4220783039 hasConcept C159654299 @default.
• W4220783039 hasConcept C163764329 @default.
• W4220783039 hasConcept C203014093 @default.
• W4220783039 hasConcept C2777699746 @default.
• W4220783039 hasConcept C2778105408 @default.

• next